- Home
- OTLK vs ITRM Comparison
OTLK vs ITRM Comparison
Compare OTLK & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ITRM
- Stock Information
- Founded
- OTLK 2010
- ITRM 2015
- Country
- OTLK United States
- ITRM Ireland
- Employees
- OTLK N/A
- ITRM N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- ITRM Health Care
- Exchange
- OTLK Nasdaq
- ITRM Nasdaq
- Market Cap
- OTLK 56.3M
- ITRM 47.7M
- IPO Year
- OTLK 2016
- ITRM 2018
- Fundamental
- Price
- OTLK $1.48
- ITRM $1.34
- Analyst Decision
- OTLK Strong Buy
- ITRM Strong Buy
- Analyst Count
- OTLK 5
- ITRM 1
- Target Price
- OTLK $10.20
- ITRM $5.00
- AVG Volume (30 Days)
- OTLK 467.0K
- ITRM 298.6K
- Earning Date
- OTLK 02-14-2025
- ITRM 02-07-2025
- Dividend Yield
- OTLK N/A
- ITRM N/A
- EPS Growth
- OTLK N/A
- ITRM N/A
- EPS
- OTLK N/A
- ITRM N/A
- Revenue
- OTLK N/A
- ITRM N/A
- Revenue This Year
- OTLK N/A
- ITRM N/A
- Revenue Next Year
- OTLK $288.46
- ITRM $160.88
- P/E Ratio
- OTLK N/A
- ITRM N/A
- Revenue Growth
- OTLK N/A
- ITRM N/A
- 52 Week Low
- OTLK $0.87
- ITRM $0.81
- 52 Week High
- OTLK $12.85
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- OTLK 41.52
- ITRM 41.28
- Support Level
- OTLK $1.38
- ITRM $1.25
- Resistance Level
- OTLK $1.56
- ITRM $1.41
- Average True Range (ATR)
- OTLK 0.12
- ITRM 0.08
- MACD
- OTLK 0.02
- ITRM 0.00
- Stochastic Oscillator
- OTLK 59.26
- ITRM 32.14
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.